Telo Genomics Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TDSGF research report →
Price Chart
About the company
Telo Genomics Corp. (TELO. V) operates as a biotechnology firm focused on creating and bringing to market advanced predictive solutions.
- CEO
- John Allen Farlinger
- IPO
- 2021
- Employees
- 8
- HQ
- Toronto, ON, CA
Get TickerSpark's AI analysis on TDSGF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.51M
- P/E
- -1.74
- PEG
- -0.02
- P/S
- 0.00
- P/B
- -2.54
- EV/EBITDA
- -2.44
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 295.03%
- ROIC
- 1561.42%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-83,618-687.8%
- Op Income
- $-2,113,242
- Net Income
- $-2,232,122+17.9%
- EPS
- $-0.02+2.6%
- OCF Growth
- +34.0%
- FCF Growth
- +33.3%
- 52W High
- $0.06
- 52W Low
- $0.02
- 50D MA
- $0.04
- 200D MA
- $0.03
- Beta
- 0.24
- RSI (14)
- 30
- Avg Volume
- 7.36K
No earnings-call transcripts are available for TDSGF yet.
- Free Float
- 97.0%
- Shares Outstanding
- 100.43M
- Float Shares
- 97.44M
Our TDSGF coverage
Recent articles, reports, and earnings notes.
No research on TDSGF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TDSGF report →Telo Genomics Corp. Announces Non-Brokered Private Placement of Secured Convertible Debentures
newsfilecorp.com · Nov 20
Telo Genomics Announces Term Sheet Providing an Option for Exclusive Worldwide License to AI Technology for Automated Detection of Rare Malignant Cells
newsfilecorp.com · Nov 18
Telo Genomics Announces $250,000 Term Loan Facility
newsfilecorp.com · Nov 6
TELO Genomics Expands Multi-Center Clinical Studies to Advance Comparative Validation of TELO-MRD Against Next-Generation Sequencing
newsfilecorp.com · Oct 29
Telo Genomics Reports Additional Clinical Research Results Comparing Blood-Based TELO-MRD with Bone-Marrow Next-Generation Flow and Next-Generation Sequencing
newsfilecorp.com · Sep 29
Telo Genomics Announces Clinical Research Results Evidencing Utility of Its Telomere Analysis Platform in Predicting Multiple Myeloma Relapse
newsfilecorp.com · Sep 15
Telo Genomics Grants Stock Options
newsfilecorp.com · Aug 4
Telo Genomics Provides Positive Interim Data from Ongoing Clinical Trial Advancing Genomic Instability-Based Relapse Risk Assessment
newsfilecorp.com · Jul 16
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.